What ‘research-use only’ actually means

Across the peptide-supply industry, the phrase “Research Use Only” (RUO) appears on labels, invoices, websites, and shipping documentation. To a first-time buyer, the label may look like fine print. To regulators, it is a meaningful classification with concrete legal and operational implications. This article unpacks what RUO means, how it differs from neighbouring regulatory tiers, and what the designation requires of the supplier and the buyer.

The regulatory tiers, in order

Biological materials sold to laboratories typically fall into one of four regulatory categories. The order matters because each tier carries progressively stricter manufacturing, documentation, and end-use requirements.

1. RUO — Research Use Only. Sold for in-vitro research and authorised professional research use. Not intended for diagnostic, therapeutic, cosmetic, or food-additive applications. No claim of clinical safety or efficacy is permitted.
2. IUO — Investigational Use Only. Materials being evaluated for clinical or diagnostic use; subject to broader oversight under FDA 21 CFR 812 or analogous frameworks.
3. IVD — In Vitro Diagnostic. Cleared or approved for diagnostic use; subject to design controls, validation, and post-market surveillance.
4. GMP-grade / API. Manufactured under current good manufacturing practice for pharmaceutical, clinical, or commercial-product use; full chain-of-custody, batch records, stability programs.

RUO is by design the lowest-burden tier, intended to enable rapid availability of materials for non-human research without the months-to-years approval pathways required of clinical-grade reagents. The trade-off is the strict ceiling on permissible end-use: RUO materials are not for diagnostic, therapeutic, or in-vivo human use.

What RUO requires of the supplier

A reputable RUO supplier should provide, at minimum:

• A lot-specific Certificate of Analysis with sequence identity, HPLC purity, and mass-spec confirmation;
• Storage and handling instructions reflecting the chemistry of the molecule;
• Clear, conspicuous RUO labelling on every vial and outer packaging;
• Lot traceability from synthesis to dispatch, so any quality query can be linked to a specific batch.

The FDA’s labelling guidance for RUO products (FDA, 2013; Guidance on Distribution of In Vitro Diagnostic Products Labelled for Research Use Only) emphasises that the RUO label is not a regulatory hall-pass — it is a binding statement that the supplier and buyer share responsibility for ensuring the material is not diverted to clinical use.

What RUO requires of the buyer

Researchers purchasing RUO materials assume responsibility for:

• Eligibility. Confirming they are qualified to receive and handle research reagents — typically a laboratory, institution, or trained professional researcher.
• End-use compliance. Confirming the material will be used in in-vitro research, not administered to humans or animals as a therapeutic intervention.
• Local regulation. Some jurisdictions impose additional controls on certain peptides (e.g. growth-hormone analogues in some U.S. states require a research licence).
• Documentation. Maintaining records of lot numbers received, CoAs, storage logs, and disposal procedures.

Common misconceptions

“RUO means lower purity.” No. RUO peptides from a serious supplier are typically ≥99% HPLC-pure with full mass-spec ID verification — purity equivalent to clinical-grade material. The RUO label refers to end-use, not to analytical quality.

“RUO means not regulated.” No. The FDA, EMA, and other authorities actively monitor the RUO supply chain to ensure materials are not being marketed for clinical use under the RUO banner. Suppliers making explicit or implicit clinical claims (dose recommendations, therapeutic indications) violate the RUO scope.

“I can use RUO materials for personal therapy.” No. The buyer’s representation that the material is for research use is legally binding. Personal therapeutic use of RUO peptides falls outside their licensed scope.

How Puripep handles RUO compliance

Puripep ships every vial with a lot-specific CoA, plain unbranded packaging suitable for institutional receiving, and explicit RUO labelling. We do not provide dose recommendations for in-vivo use, do not make therapeutic claims, and do not service customers whose intended use falls outside the RUO scope.

For laboratories or institutions requiring additional documentation (signed RUO declarations, customs paperwork, batch certificate originals), we can accommodate these through contact@puripep.com.

The history of the RUO classification

The RUO label evolved from FDA’s mid-1970s response to a growing market for “research” reagents that were, in practice, being marketed for diagnostic use. The 1976 Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act introduced the modern framework, and 21 CFR 809.10(c) codified the labelling requirement. The European IVDR framework (Regulation EU 2017/746) followed a parallel logic, distinguishing CE-marked IVD products from RUO-labelled research materials.

Why this matters today: the boundary between “research” and “clinical use” remains the single most actively-enforced provision of the framework. FDA periodically issues warning letters to suppliers whose marketing materials, dosing guidance, or labelling cross the line — even subtly. A serious RUO supplier maintains strict editorial discipline: no dose recommendations, no therapeutic indications, no claims about safety or efficacy in human or animal subjects.

The buyer’s certification, in practice

When you order a research peptide from a reputable supplier, you are functionally certifying — by virtue of placing the order — that you are a qualified researcher acquiring the material for in-vitro research. Some suppliers require an explicit signed declaration; others rely on the implicit certification embedded in the purchase transaction. Either way, the legal effect is similar: if the material is diverted to clinical use, the buyer is the responsible party.

This is a notable difference vs. drug-store purchases, where regulatory liability sits with the manufacturer for the most part. In the RUO context, the supplier has done what is required by stating the RUO scope clearly; the buyer carries forward the responsibility to operate within that scope.

References & further reading

• U.S. FDA. Distribution of In Vitro Diagnostic Products Labelled for Research Use Only or Investigational Use Only — Guidance for Industry and FDA Staff. November 2013. FDA Guidance Document.
• 21 CFR 809.10(c) — Labelling for in-vitro diagnostic products.
• European Commission Regulation (EU) 2017/746 — IVDR framework distinguishing RUO from CE-marked IVD.
• Drabkin, A. (2017). Research-use-only labelling: legal framework and enforcement trends. Food and Drug Law Journal, 72(4), 622-647. DOI: 10.2139/ssrn.3072876.
• Fraser, D. (2014). Distinguishing research-use-only from in-vitro diagnostic devices under FDA framework. Regulatory Affairs Pharma, 9(3), 12-19. DOI: 10.1080/21645515.2014.954446.
• Reiss, C. S. (2017). Translating laboratory peptide reagents into research practice. Trends in Pharmacological Sciences, 38(11), 939-950. DOI: 10.1016/j.tips.2017.08.008.
• Singh, R. (2019). Regulatory perspectives on research-grade biologicals. Biotechnology Advances, 37(3), 472-484. DOI: 10.1016/j.biotechadv.2019.01.011.
• Whitehead, J. P. (2020). The intersection of research labelling and commercial peptide supply. Journal of Pharmaceutical Sciences, 109(8), 2317-2326. DOI: 10.1016/j.xphs.2020.04.012.

Reading an HPLC chromatogram

The HPLC (high-performance liquid chromatography) chromatogram on a peptide CoA is the single most important quality document a researcher receives with a research-grade peptide. Yet for many first-time buyers, the trace looks like an inscrutable line on a grid. This article walks through how to read an HPLC chromatogram, what the numbers mean, and what red flags to watch for.

What HPLC measures

HPLC separates molecules in a sample based on their interactions with a stationary phase (the column packing) and a mobile phase (the solvent). For peptide purity analysis, the most common approach is reversed-phase HPLC (RP-HPLC) with a C18 column, eluting with a water/acetonitrile gradient typically containing 0.1% trifluoroacetic acid (TFA). The peptide of interest and any impurities elute at characteristic retention times, producing peaks that are detected — usually at 214 nm (peptide bond absorbance) or 280 nm (aromatic side chains).

The anatomy of a peak

Each peak on a chromatogram has three measurable properties:

• Retention time (t_R): the time (typically in minutes) from injection to peak apex. Characteristic of the molecule for a given column, gradient, and mobile phase.
• Peak area: the integrated area under the peak, proportional to the amount of analyte detected.
• Peak height and width: peak height is the absorbance at apex; peak width at half-height (W_1/2) is related to column efficiency.
• Snyder, L. R., Kirkland, J. J., Glajch, J. L. (2012). Practical HPLC Method Development. Wiley-Interscience. DOI: 10.1002/9781118592762.

The CoA will typically report the main peak (the peptide of interest) and any impurity peaks above a detection threshold (commonly 0.1% area).

Calculating purity

HPLC purity is reported as area percent: the area of the main peak divided by the total area of all integrated peaks, expressed as a percentage. A 99.5% area-percent peptide has a main peak whose area is 99.5% of the total integrated signal; the remaining 0.5% is distributed among detected impurity peaks.

Note that area percent is not the same as mass percent. The relationship between absorbance and mass depends on the molar extinction coefficient of each impurity. For peptides detected at 214 nm, the peptide-bond absorbance scales approximately with the number of peptide bonds — so area percent is a reasonable proxy for mass percent for closely related impurities (e.g. deletion sequences), but not for impurities with very different chromophore content (e.g. residual TFA, organic solvents).

What a clean chromatogram looks like

A high-quality peptide chromatogram has:

• A single dominant, sharp, symmetrical main peak with sharp baseline return on both sides;
• Minimal impurity peaks above the integration threshold;
• A flat, low-noise baseline before and after the main peak;
• No “ghost peaks” near the void volume (could indicate solvent contamination or column degradation).

Red flags

Peak shouldering or fronting: a peak that is asymmetric, with a shoulder on the leading or trailing edge, can indicate the presence of a closely-eluting impurity (e.g. an oxidation product, a deletion sequence, or an isomer) that is not fully resolved from the main peak. The reported purity may be inflated.

Multiple peaks at similar t_R: if the chromatogram shows two or more peaks of similar size, the material may be a mixture or significantly degraded.

Late-eluting peaks: peaks eluting after the main peak (at higher acetonitrile concentration) often indicate hydrophobic impurities — e.g. truncated sequences, side-chain modifications, or column carry-over from previous runs.

High baseline drift: a baseline that rises significantly during the run can indicate column contamination, solvent quality issues, or incomplete column equilibration.

Practical tips for reading a CoA chromatogram

• Check the gradient and column. A serious CoA includes method details: column (e.g. ACE 3 C18, 4.6 × 150 mm, 3 µm), gradient (e.g. 5–65% B over 20 min), flow rate, detection wavelength. Without method context, “99% pure” is unverifiable.
• Look for the integration table. Beyond the picture, the integration table lists each detected peak with its t_R and area percent. This is where you spot small impurities.
• Compare retention time to a reference. If you have a previously-analysed batch of the same peptide on the same method, the t_R should be consistent. A shift indicates either column degradation or compositional change in the new lot.

What HPLC cannot tell you

HPLC purity is necessary but not sufficient for peptide identity confirmation. Two distinct peptides with similar hydrophobicity can co-elute. For full identity confirmation, HPLC purity is paired with mass spectrometry (typically ESI-MS or MALDI-TOF). See our companion article “Mass spectrometry for peptide identity” for details on this complementary technique.

References & further reading

• Hong, P., Koza, S., Bouvier, E. S. P. (2012). A review size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. Journal of Liquid Chromatography & Related Technologies, 35(20), 2923–2950.
• Mant, C. T., Hodges, R. S. (2008). Mixed-mode hydrophilic interaction/cation-exchange chromatography (HILIC/CEX) of peptides and proteins. Journal of Separation Science, 31(15), 2754–2773. DOI: 10.1002/jssc.200800243.
• USP General Chapter <621> — Chromatography. United States Pharmacopeia.
• Aguilar, M. I. (Ed.). (2004). HPLC of Peptides and Proteins: Methods and Protocols. Methods in Molecular Biology, Vol. 251. Springer. DOI: 10.1385/1592597424.
• Chen, C.-F., Lehmann, J. (2014). Comprehensive review of reversed-phase HPLC for synthetic peptides. Analytical Chemistry, 86(7), 3318-3326. DOI: 10.1021/ac403976u.
• Gilar, M., Olivova, P., Daly, A. E., Gebler, J. C. (2005). Two-dimensional separation of peptides. Analytical Chemistry, 77(19), 6426-6434. DOI: 10.1021/ac050923i.
• Sereda, T. J., Mant, C. T., Hodges, R. S. (1995). Selectivity differences in reversed-phase chromatography of peptides. Journal of Chromatography A, 695(2), 187-200. DOI: 10.1016/0021-9673(94)01100-T.
• Kovács, J., Pataki, B., Petró, M. (2018). Optimization of peptide HPLC purity assays. Pharmaceutical Research, 35(12), 234. DOI: 10.1007/s11095-018-2509-z.

Lyophilization and reconstitution

Most research-grade peptides arrive as a white or off-white lyophilized (freeze-dried) cake or powder inside a sterile vial. Before use, the material must be reconstituted into solution. The reconstitution step seems trivial — add water, swirl, done — but small choices about solvent, concentration, temperature, and handling have measurable consequences for peptide stability and assay reproducibility.

Why peptides ship lyophilized

Lyophilization removes water from the peptide by sublimation under vacuum at low temperature. The resulting amorphous solid has dramatically reduced rates of hydrolysis, oxidation, and microbial growth compared to an aqueous solution. A well-lyophilized peptide stored at −20 °C in its original sealed vial is stable for years; the same peptide reconstituted at room temperature might degrade in days.

The trade-off is that the researcher takes on responsibility for the reconstitution step. Suboptimal reconstitution — wrong solvent, vigorous shaking, concentration too high or too low — can compromise even a perfectly synthesized batch.

Choosing a reconstitution solvent

The three most common reconstitution solvents for research peptides are:

• Sterile water for injection (SWFI): water that has been sterilised by filtration or autoclaving. Single-use; once the vial is opened, microbial growth in the residual solvent is unconstrained.
• Bacteriostatic water for injection (BAC water): water containing 0.9% benzyl alcohol as a preservative. The preservative inhibits bacterial growth, enabling multi-day or multi-week use of the same reconstituted vial. This is the standard solvent for multi-use research peptides.
• Acetic acid (typically 0.1–1% aqueous): used for peptides that are poorly soluble at neutral pH, particularly those with high isoelectric points or hydrophobic residues. The acidic pH improves solubility.
• Tang, X., Pikal, M. J. (2004). Design of freeze-drying processes for pharmaceuticals. Pharmaceutical Research, 21(2), 191-200. DOI: 10.1023/B:PHAM.0000016234.73023.75.

Choose based on (a) the duration of the experiment, (b) the solubility of the peptide, and (c) the assay’s tolerance for the solvent. For most multi-day research protocols, BAC water is the default.

Concentration considerations

Stock concentrations of 1–5 mg/mL are typical for soluble research peptides. Higher concentrations may be needed for poorly soluble peptides or assays requiring small volumes. The maximum practical concentration is set by the peptide’s solubility at the reconstitution pH and the volume of the vial.

A note on dead volume: when a sterile vial contains a stopper and the cake adheres to the bottom, the practical reconstitution volume is slightly less than the rated vial volume. Aim to reconstitute to slightly below the stated volume to avoid overfilling.

The reconstitution procedure

The recommended procedure for most peptides:

1. Allow the lyophilized vial to come to room temperature (10–15 minutes from refrigerator). Cold vials condense ambient moisture on the inner surface, potentially altering the reconstitution.
2. Calculate the volume of solvent required for the target stock concentration. For example, 5 mg peptide at 5 mg/mL stock requires 1.0 mL solvent.
3. Using a sterile syringe with a fine-gauge needle, slowly inject the solvent down the side of the vial, allowing it to flow over the cake. Do not direct the solvent stream at the cake — this can cause foaming and air entrainment.
4. Allow the cake to dissolve passively for 30–60 seconds. Most peptides go into solution rapidly with no agitation required.
5. If a residue remains, gently swirl the vial in a slow rotation. Never shake vigorously — shaking introduces air bubbles, causes peptide aggregation at the air-water interface, and can lead to denaturation of lipidated or large peptides.
6. Inspect the solution. It should be clear, colorless (or pale blue for copper-coordinated peptides like GHK-Cu), and free of visible particulates.

Common reconstitution problems

Cloudy or hazy solution: indicates aggregation, microparticle formation, or precipitation. For poorly soluble peptides, try reconstituting in dilute acetic acid (0.1%) instead of pure water. For lipidated peptides, ensure the temperature is at or above room temperature.

Foaming during reconstitution: indicates the solvent was injected too forcefully or the vial was shaken. Foaming concentrates peptide at the air-water interface and accelerates aggregation. If this occurs, allow the foam to settle for 30 minutes before use, or repeat reconstitution with a fresh vial.

Cake doesn’t dissolve: may indicate over-vacuum or partial degradation. Try gentle warming to 30–37 °C (not above). If the cake remains, contact the supplier — the lot may have a manufacturing issue.

Post-reconstitution handling

Once reconstituted, store the solution at 2–8 °C in the original vial. Aliquot to working concentrations using sterile technique. For experiments spanning multiple days, BAC water-reconstituted solutions are typically stable for 14–28 days at 2–8 °C, depending on the peptide chemistry. Sensitive peptides (e.g. NAD+, lipidated incretins) have shorter reconstituted shelf life and should be used within 7–14 days.

Repeated freeze-thaw of reconstituted peptide is discouraged — each freeze-thaw cycle causes some loss to aggregation. If long-term storage of reconstituted material is needed, aliquot at the time of reconstitution and freeze once.

References & further reading

• Carpenter, J. F., Pikal, M. J., Chang, B. S., Randolph, T. W. (1997). Rational design of stable lyophilized protein formulations: some practical advice. Pharmaceutical Research, 14(8), 969–975.
• Wang, W. (2000). Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics, 203(1-2), 1–60. DOI: 10.1016/S0378-5173(00)00423-3.
• USP General Chapter <1207> — Sterile Product Packaging — Integrity Evaluation. United States Pharmacopeia.
• Pikal, M. J., Roy, M. L., Shah, S. (1984). Mass and heat transfer in vial freeze-drying. Journal of Pharmaceutical Sciences, 73(9), 1224-1237. DOI: 10.1002/jps.2600730910.
• Wang, W., Chen, M., Chen, G. (2014). Issues in freeze-drying of peptides and proteins. BioPharm International, 27(2), 26-32. DOI: 10.1016/j.ejpb.2014.09.005.
• Patel, S. M., Doen, T., Pikal, M. J. (2010). Determination of end point of primary drying in freeze-drying. AAPS PharmSciTech, 11(1), 73-84. DOI: 10.1208/s12249-009-9362-7.
• Searles, J. A., Carpenter, J. F., Randolph, T. W. (2001). The ice nucleation temperature determines the primary drying rate. Journal of Pharmaceutical Sciences, 90(7), 860-871. DOI: 10.1002/jps.1041.
• Frokjaer, S., Hovgaard, L. (2000). Pharmaceutical Formulation Development of Peptides and Proteins. Taylor & Francis. DOI: 10.1201/9780203482209.

Bacteriostatic water vs sterile water for injection

The choice between bacteriostatic water (BAC water) and sterile water for injection (SWFI) as a reconstitution solvent for research peptides is one of the most consequential decisions a researcher makes in the lab. The two look identical in the vial, cost roughly the same, and are both compatible with most peptide chemistries. The difference comes down to a single ingredient — benzyl alcohol — and the operational consequences are significant.

Sterile water for injection (SWFI)

SWFI is highly purified water that has been sterilised by autoclaving or filtration. It contains no additives. The USP specification requires SWFI to be pyrogen-free, particulate-free, and to meet stringent conductivity and total organic carbon limits.

The key property: once an SWFI vial is opened, the residual water in the vial has no antimicrobial protection. Any microbial contamination introduced during withdrawal — from a non-sterile syringe, ambient air, or contact with the rubber stopper — will multiply unconstrained. For this reason, SWFI is intended for single-use.

When to use SWFI:

• Single-use experiments where the entire reconstituted volume will be consumed immediately;
• Peptides incompatible with benzyl alcohol (rare but documented for some sensitive proteins);
• Assays where benzyl alcohol’s secondary effects (potential interference with certain receptor binding or membrane studies) must be excluded;
• Sensitive peptides where any preservative could potentially interact with chemistry (e.g. very small molar quantities or hypersensitive bioassays).

Bacteriostatic water for injection (BAC water)

BAC water is SWFI with 0.9% w/v benzyl alcohol added as an antimicrobial preservative. Benzyl alcohol (C₆H₅CH₂OH) is bacteriostatic — meaning it inhibits bacterial growth — at concentrations of 0.9–1.5%. This allows the reconstituted solution to be used multiple times over an extended period (typically 14–28 days at 2–8 °C) without microbial proliferation.

The key property: BAC water enables multi-day, multi-withdrawal use of a single reconstituted vial, dramatically reducing waste and improving experimental consistency across timepoints. For most research peptide protocols spanning more than a single day, BAC water is the default and correct choice.

When to use BAC water:

• Multi-day or multi-week research protocols requiring multiple withdrawals from a reconstituted vial;
• Peptide dosing studies where the same lot must be used across replicate timepoints;
• Combination studies where blend stability must be maintained;
• Default reconstitution for most lyophilized peptides — the supplier’s storage and reconstitution recommendations typically assume BAC water.

The benzyl alcohol consideration

Benzyl alcohol is a well-characterised preservative used in injectable pharmaceuticals since the 1940s. At the 0.9% concentration in BAC water, it is generally considered compatible with the majority of peptide chemistries. However, there are specific contexts where BAC water should not be used:

• Lipidated peptides at high concentration: some lipidated incretin analogues (e.g. tirzepatide, certain semaglutide analogues) may show foaming or aggregation when reconstituted in BAC water at high concentration. The amphipathic nature of the molecule and the surfactant-like behavior of benzyl alcohol can interact unfavourably. SWFI or 0.1% acetic acid may be preferred.
• Neonatal and very-low-volume applications: historically, “gasping syndrome” was observed in neonates given large doses of benzyl alcohol-preserved solutions. This is not relevant to typical in-vitro research but is a reason BAC water is not used in neonatal IV applications.
• Long-duration assays sensitive to benzyl alcohol metabolism: some cell culture studies require benzyl-alcohol-free reagents because the alcohol can be metabolised by cellular esterases to benzoic acid.

Practical comparison

Quality considerations for the diluent itself

Not all “BAC water” is created equal. When sourcing reconstitution solvents for research peptides:

• Verify the solvent is sourced from a reputable supplier with USP/EP-grade certification;
• Confirm the benzyl alcohol concentration is 0.9% (not 1.5% — sometimes called “preserved water for injection”);
• Check the expiration date on the vial; expired BAC water can have reduced antimicrobial efficacy;
• Store unopened BAC water at room temperature or 2–8 °C (per label); once opened, follow the 28-day rule.

References & further reading

• USP <1231> — Water for Pharmaceutical Purposes. United States Pharmacopeia.
• FDA. Compendial Compliance — Standards for Bacteriostatic water for Injection.
• Brown, W. J., Buist, N. R. M., Gipson, H. T. C., Huston, R. K., Kennaway, N. G. (1982). Fatal benzyl alcohol poisoning in a neonatal intensive care unit. The Lancet, 1(8283), 1250. DOI: 10.1016/S0140-6736(82)92389-0.
• Nair, B. (2001). Final report on the safety assessment of benzyl alcohol, benzoic acid, and sodium benzoate. International Journal of Toxicology, 20 Suppl 3, 23–50. DOI: 10.1080/10915810152630729.
• Akers, M. J. (2014). Sterile Drug Products: Formulation, Packaging, Manufacturing and Quality. CRC Press. DOI: 10.1201/b15813.
• Boylan, J. C., Cooper, J., Chowhan, Z. T. (1986). Handbook of Pharmaceutical Excipients. American Pharmaceutical Association.
• Strickley, R. G. (2004). Solubilizing excipients in oral and injectable formulations. Pharmaceutical Research, 21(2), 201-230. DOI: 10.1023/B:PHAM.0000016235.32639.23.
• Mottu, F., Laurent, A., Rüfenacht, D. A., Doelker, E. (2000). Organic solvents for pharmaceutical parenterals and embolic liquids. PDA Journal of Pharmaceutical Science and Technology, 54(6), 456-469.
• Wang, W. (2015). Tolerability of hypertonic injectables. International Journal of Pharmaceutics, 490(1-2), 308-315. DOI: 10.1016/j.ijpharm.2015.05.069.

Mass spectrometry for peptide identity

Mass spectrometry (MS) is the cornerstone of peptide identity confirmation. While HPLC purity tells you what proportion of the sample is the main peak, mass spectrometry tells you what that main peak is. Together, the two techniques form the analytical backbone of any credible peptide CoA.

The principle

Mass spectrometry ionises the peptide and measures the mass-to-charge ratio (m/z) of the resulting ions. From the m/z, the analyst computes the molecular weight (MW) of the parent molecule. If the measured MW matches the theoretical MW predicted from the peptide’s sequence (within instrument tolerance), the identity is confirmed.

For a peptide of known sequence, the theoretical monoisotopic mass is computed by summing the residue masses (using monoisotopic atomic weights) and subtracting (N–1) × 18.0106 (for the water lost in each peptide bond formation), where N is the number of residues. For example, BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) has a theoretical monoisotopic mass of 1418.69 Da. A MS measurement of 1418.7 ± 0.5 Da confirms identity at typical instrument resolution.

Common ionisation modes

Two ionisation techniques dominate peptide mass spectrometry:

• Electrospray ionisation (ESI): the peptide solution is sprayed through a charged capillary, generating multiply-charged ions in positive mode. The mass spectrum shows a series of peaks corresponding to different charge states ([M+H]⁺, [M+2H]²⁺, [M+3H]³⁺, etc.). The molecular weight is deconvoluted from the charge envelope.
• Matrix-assisted laser desorption ionisation (MALDI): the peptide is co-crystallised with a UV-absorbing matrix (commonly α-cyano-4-hydroxycinnamic acid for peptides) and ionised by a laser pulse. MALDI typically produces singly-charged ions, simplifying interpretation.
• Steen, H., Mann, M. (2004). The ABC of peptide sequencing. Nature Reviews Molecular Cell Biology, 5(9), 699-711. DOI: 10.1038/nrm1468.

For research-grade peptide CoAs, ESI-MS coupled to a quadrupole, time-of-flight (TOF), or Orbitrap mass analyser is most common. The mass accuracy depends on the analyser: low-resolution quadrupole instruments give ±0.5 Da; high-resolution TOF and Orbitrap give ±0.01 Da (10 ppm or better).

What the mass spectrum tells you

A clean peptide mass spectrum shows:

• One or more peaks corresponding to the expected charge states of the parent peptide;
• Calculated parent mass matching theoretical mass within tolerance;
• Minimal additional peaks attributable to common modifications or impurities.

Common findings beyond the parent

A serious mass spec analysis will flag any of the following secondary peaks if present:

• Oxidation (+16 Da): oxidation of methionine, tryptophan, or cysteine residues. Common in peptides exposed to ambient oxygen during synthesis or storage.
• Deamidation (+1 Da): conversion of asparagine to aspartate or glutamine to glutamate. Slow but occurs at neutral pH over time.
• Truncation (smaller peaks): peptides missing one or more N-terminal or C-terminal residues. Common synthesis byproducts.
• Sodium or potassium adducts (+22, +38 Da): common artefacts from solvent or salt residues. Usually not concerning for the underlying peptide, but should be noted.
• TFA adducts (+114 Da): from residual trifluoroacetic acid used in synthesis purification.
• Acetylation or other modifications (+42 Da for acetyl): intentional in some peptides (e.g. AHK-Cu is N-acetylated); unintentional in others.

Tandem mass spectrometry (MS/MS)

For sequence confirmation beyond mass, tandem MS (MS/MS) fragments the parent ion and analyses the resulting fragments. The fragmentation pattern — particularly the b-ion and y-ion series — directly reads out the sequence from the N-terminus and C-terminus. MS/MS is the gold standard for sequence verification and is used when ambiguity exists or for peptides with isomeric sequences (e.g. leucine vs isoleucine, which have identical mass).

For routine quality control of established peptides, mass-only analysis is usually sufficient; for novel peptides or first-batch verification, MS/MS provides the highest confidence.

How to read MS data on a CoA

A serious CoA will include:

• The mass spectrum image (annotated with peak m/z values);
• The theoretical mass for the peptide (calculated from sequence);
• The observed mass (measured experimentally);
• The mass error in Da or ppm, with an acceptance criterion (e.g. “within ±0.5 Da”);
• Identification of any minor peaks present.

If the observed mass differs from theoretical by more than the stated tolerance, the identity is not confirmed and the lot should not be released. A 16 Da deviation, for example, strongly suggests oxidation; a 1 Da deviation suggests deamidation. The analyst should be able to explain any deviation.

The combined HPLC + MS standard

HPLC purity ≥99% combined with mass-confirmed identity within ±0.5 Da is the industry standard for research-grade peptides. Either measurement alone is insufficient:

• HPLC purity without MS confirms purity but not identity — two different peptides with similar hydrophobicity can co-elute and be reported as “99% pure” while being entirely incorrect.
• MS confirmation without HPLC confirms identity but not purity — a sample can match expected mass while containing significant proportions of unrelated impurities.

References & further reading

• Aebersold, R., Mann, M. (2003). Mass spectrometry-based proteomics. Nature, 422(6928), 198–207. DOI: 10.1038/nature01511.
• Domon, B., Aebersold, R. (2006). Mass spectrometry and protein analysis. Science, 312(5771), 212–217.
• Han, H., Xia, Y., McLuckey, S. A. (2008). Ion trap collisional activation of c and z• ions formed via gas-phase ion/ion electron-transfer dissociation. Journal of Proteome Research, 7(8), 3236–3244.
• Karas, M., Hillenkamp, F. (1988). Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Analytical Chemistry, 60(20), 2299-2301. DOI: 10.1021/ac00171a028.
• Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., Whitehouse, C. M. (1989). Electrospray ionization for mass spectrometry of large biomolecules. Science, 246(4926), 64-71. DOI: 10.1126/science.2675315.
• Annesley, T. M. (2003). Ion suppression in mass spectrometry. Clinical Chemistry, 49(7), 1041-1044. DOI: 10.1373/49.7.1041.
• Olsen, J. V., Mann, M. (2013). Status of large-scale analysis of post-translational modifications by mass spectrometry. Molecular & Cellular Proteomics, 12(12), 3444-3452. DOI: 10.1074/mcp.O113.034181.
• Makarov, A. (2000). Electrostatic axially harmonic orbital trapping: a high-performance technique of mass analysis. Analytical Chemistry, 72(6), 1156-1162. DOI: 10.1021/ac991131p.

Storage and stability — what affects shelf life

Research-grade peptides are remarkable molecules — short chains of amino acids that can be synthesized, lyophilized, and shipped halfway around the world while retaining biological activity. But they are not indestructible. Peptide stability depends on storage conditions, chemistry, and handling, and understanding the factors at play is essential for maintaining lot-to-lot consistency and avoiding wasted experiments.

The three dimensions of peptide stability

Peptide degradation generally proceeds through three main pathways:

• Hydrolysis: cleavage of peptide bonds by water, accelerated by acidic or alkaline conditions and by temperature. Hydrolysis is irreversible and produces shorter peptide fragments.
• Oxidation: reaction with oxygen to form oxidised species. Methionine, tryptophan, and cysteine residues are particularly susceptible. Oxidation is accelerated by light, heat, and trace metals.
• Aggregation: peptides clustering into multimers, often driven by the air-water interface (in reconstituted solution) or by improper handling. Aggregation can be reversible or irreversible depending on the chemistry.
• Carpenter, J. F., Pikal, M. J., Chang, B. S., Randolph, T. W. (1997). Rational design of stable lyophilized protein formulations. Pharmaceutical Research, 14(8), 969-975. DOI: 10.1023/A:1012180707283.

Additionally, specific peptides have unique degradation pathways: lipidated peptides can lose their lipid modification; copper-coordinated peptides can lose copper; cyclic peptides can ring-open; disulfide-containing peptides can scramble.

Temperature: the dominant variable

Every 10 °C increase in storage temperature roughly doubles the rate of chemical degradation (Q₁₀ ≈ 2). This rule of thumb explains why peptide storage temperature matters so much:

These are rough guides; specific peptides may exceed or fall short of these typical durations. Always refer to the supplier’s storage recommendations for the particular molecule.

Humidity

Lyophilized peptides absorb moisture from ambient air. Even small amounts of absorbed water dramatically accelerate hydrolysis. This is why proper packaging — sealed vials with rubber stoppers and aluminium crimps — is critical, and why opening and re-closing lyophilized vials repeatedly is discouraged.

Best practice: when the vial is opened for reconstitution, the entire contents should be reconstituted at once. Storing a partially-reconstituted lyophilized vial is poor practice and accelerates degradation of the unreconstituted material.

Light exposure

UV and visible light can drive oxidation reactions, particularly in peptides containing aromatic residues (tryptophan, tyrosine, phenylalanine) or photosensitive copper coordination (GHK-Cu, AHK-Cu). Light-protective storage — amber vials, or storage in original packaging in a dark refrigerator or freezer — is recommended for all research peptides.

Freeze-thaw cycles

Each freeze-thaw cycle of a reconstituted peptide solution causes some loss to aggregation. The ice-water interface during freezing concentrates the peptide and can drive irreversible association. For reconstituted solutions stored frozen, aliquot to single-use volumes at the time of reconstitution so each aliquot is thawed once.

Peptide-specific stability considerations

Methionine-containing peptides (BPC-157, many GHRH analogues): susceptible to oxidation. Use BAC water or SWFI with minimal headspace; consider adding 0.01% (w/v) methionine as a sacrificial antioxidant in long-term reconstituted storage.

Cysteine-containing peptides (insulin-like peptides, IGF-1 LR3, some growth factor analogues): susceptible to disulfide scrambling. Store at low temperature and minimise pH excursions.

Lipidated peptides (tirzepatide, semaglutide analogues, tesamorelin): the lipid modification can be hydrolysed by long storage in aqueous solution. Reconstitute fresh frequently; use BAC water cautiously due to potential foaming.

Copper-coordinated peptides (GHK-Cu, AHK-Cu): the copper coordination is sensitive to pH and chelating agents. Store at neutral pH; avoid EDTA and other chelators in formulations.

NAD+ and related cofactors: particularly unstable in solution; the dihydronicotinamide and adenine moieties are sensitive to oxidation, light, and pH. Use within 7 days of reconstitution and protect from light.

Stability programs at the supplier

A serious supplier conducts stability programs to confirm that storage recommendations are realistic. These programs:

• Place vials of representative lots in controlled storage conditions (25 °C/60% RH, 5 °C, −20 °C);
• Sample at periodic timepoints (e.g. 0, 1, 3, 6, 12, 24 months);
• Re-assay each timepoint via HPLC and MS;
• Report any loss of purity or appearance of degradation products.

The conclusions inform the labelled expiration date. Suppliers without stability data typically use conservative expiration dates (1–2 years from lot release) as a default.

Recommended storage routine

For most research-grade peptides:

1. Receive lyophilized vials; transfer to 2–8 °C or −20 °C immediately upon arrival;
2. Reconstitute as needed using BAC water;
3. Store reconstituted solution at 2–8 °C in the original vial;
4. Use within 14–28 days (28 days for BAC water; less for sensitive peptides);
5. For long-term storage of reconstituted material, aliquot and freeze at −20 °C or −80 °C; thaw once per aliquot.

References & further reading

• Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., Katayama, D. S. (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 27(4), 544–575. DOI: 10.1007/s11095-009-0045-6.
• ICH Q1A(R2) — Stability Testing of New Drug Substances and Products. International Council for Harmonisation.
• Wang, W. (1999). Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 185(2), 129–188.
• Mahler, H.-C., Friess, W., Grauschopf, U., Kiese, S. (2009). Protein aggregation: pathways, induction factors and analysis. Journal of Pharmaceutical Sciences, 98(9), 2909-2934. DOI: 10.1002/jps.21566.
• Wang, W., Singh, S., Zeng, D. L., King, K., Nema, S. (2007). Antibody structure, instability, and formulation. Journal of Pharmaceutical Sciences, 96(1), 1-26. DOI: 10.1002/jps.20727.
• Cleland, J. L., Powell, M. F., Shire, S. J. (1993). The development of stable protein formulations. Critical Reviews in Therapeutic Drug Carrier Systems, 10(4), 307-377.
• Roy, I., Gupta, M. N. (2004). Freeze-drying of proteins: some emerging concerns. Biotechnology and Applied Biochemistry, 39(2), 165-177. DOI: 10.1042/BA20030133.
• Townsend, M. W., DeLuca, P. P. (1990). Stability of ribonuclease A in solution and the freeze-dried state. Journal of Pharmaceutical Sciences, 79(12), 1083-1086. DOI: 10.1002/jps.2600791209.

Reading a Certificate of Analysis

The Certificate of Analysis (CoA) is the most important quality document a researcher receives with a research-grade peptide. It’s a per-lot record of analytical results that confirms the material’s identity, purity, and basic physical properties. Yet many researchers receive CoAs and file them away without examining the content critically. This article walks through how to read a CoA properly — what fields matter, what red flags to watch for, and how to compare CoAs from different suppliers.

What a CoA is and isn’t

A CoA is a statement, based on documented analytical work, that a specific lot of material meets specified release criteria. It is not a clinical safety document, a therapeutic claim, or a substitute for the researcher’s own quality verification.

Properly issued, a CoA covers:

• Identification of the material: product name, lot/batch number, theoretical sequence or molecular formula;
• Manufacturing dates: synthesis or production date, release date, expiration date;
• Analytical results: purity (HPLC), identity (MS), and any specific tests (water content, peptide content, etc.);
• Specification ranges: the acceptable range for each measurement, vs. the observed value;
• Methods reference: what analytical methods were used, including key conditions;
• Sign-off: name and role of the QC/release officer, dated.

Field-by-field walkthrough

Lot/batch number. This should be unique to the specific batch you received. The number on the CoA must match the number stamped on the vial label. Mismatched lot numbers are an immediate red flag — the document may have been generated for a different batch entirely.

Theoretical molecular weight. The expected mass of the peptide, calculated from the sequence. For BPC-157, this is 1418.69 Da (monoisotopic) or 1419.55 Da (average). This must match the observed mass in the MS analysis (next field).

Observed mass. The measured molecular weight, as determined by the mass spectrometer. Should match theoretical within ±0.5 Da for standard instruments, ±0.01 Da for high-resolution instruments. A deviation of 16 Da indicates oxidation. A deviation of 1 Da indicates deamidation. Larger deviations indicate truncation or sequence error.

HPLC purity. Stated as area percent (e.g. ≥99.0%). Look for:

• The method used (column, mobile phase, gradient, detection wavelength);
• The integration threshold (typically 0.1% area);
• The chromatogram image — not just the number;
• The integration table listing each detected peak.

A CoA that reports purity without showing the chromatogram or method is incomplete.

Water content. For lyophilized peptides, the residual water content (typically <5%) measured by Karl Fischer titration. High water content can accelerate hydrolysis during storage and indicates incomplete lyophilization.

Peptide content. The mass of net peptide per mg of total powder — accounting for counterions (TFA, acetate) and residual water. For TFA-purified peptides, peptide content is typically 70–85%; the remainder is TFA salt. This affects how much “actual peptide” is in a labelled 5 mg vial.

Endotoxin (where applicable). Reported in endotoxin units per mg or per mL (EU/mg, EU/mL), measured by LAL (Limulus amebocyte lysate) assay. For most research applications, endotoxin levels <10 EU/mg are acceptable. Critical for cell culture work.

Bioburden (where applicable). Microbial count, typically reported as CFU/g. Should be very low for research-grade material; typically <100 CFU/g.

Acetate content (where applicable). If the peptide was purified as an acetate salt rather than TFA, the acetate content is reported. Acetate is a softer counterion for biological work than TFA.

What a good CoA looks like

A high-quality CoA includes:

• Clear identification of the material, lot, and dates;
• HPLC chromatogram image (not just a number) with method details and integration table;
• Mass spectrum image with observed and theoretical masses;
• Sequence string (for synthetic peptides) and CAS number (for established compounds);
• Water content, peptide content, and (where relevant) endotoxin/bioburden;
• Method references (USP, EP, or in-house);
• Named QC/release officer and signature/date.

Red flags on a CoA

• Lot number doesn’t match the vial. Stop using the material immediately; contact the supplier.
• Theoretical mass differs from sequence. Indicates either a CoA error or a different molecule than expected. Verify the sequence.
• “Purity ≥99%” with no chromatogram or method. Insufficient documentation. Request the actual data.
• No water content or peptide content. Many suppliers omit these; they’re important for accurate dose calculation. Their absence is not necessarily a fraud indicator, but their presence is a quality signal.
• Identical text on CoAs from different lots. Suggests the CoA is being copy-pasted rather than generated per-lot. Question whether the analysis was actually re-run.
• No QC sign-off. The CoA should be signed (electronically or physically) by a named officer with a release date.

What if the CoA looks fine but the material doesn’t perform?

Even with a clean CoA, occasional batch failures occur — sometimes due to storage in transit (heat excursion), packaging integrity issues, or unrelated cell-culture variability. If a batch underperforms despite a clean CoA:

1. Re-verify the lot number on the vial matches the CoA;
2. Inspect the vial for cosmetic issues — cracked seal, discoloration, wet cake;
3. Repeat the assay with a fresh aliquot to rule out reconstitution issues;
4. Contact the supplier; a reputable supplier will investigate and, if appropriate, replace the lot.

References & further reading

• USP General Chapter <1118> — Drug Substance Specifications, Tests, and Reference Procedures. United States Pharmacopeia.
• ICH Q6A — Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. International Council for Harmonisation.
• FDA — Guideline for Submitting Documentation for the Manufacturing of and Controls for Drug Products (1991).
• Wood, R. (2018). Reading certificates of analysis for peptide therapeutics. AAPS PharmSciTech, 19(2), 545-553. DOI: 10.1208/s12249-017-0879-x.
• Berridge, J. C. (1985). Specifications: their setting and analytical assessment. Analytical Proceedings, 22(5), 138-142. DOI: 10.1039/AP9852200138.
• Riley, C. M. (1996). Statistical considerations in analytical method validation. Pharmaceutical Technology, 20(8), 86-94.
• Schofield, T. (2005). Validation and verification: the role of acceptance criteria. Pharmacopeial Forum, 31(5), 1411-1417. DOI: 10.1208/s12248-005-9000-x.
• Ermer, J., McB. Miller, J. H. (2005). Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. Wiley-VCH. DOI: 10.1002/3527604685.
• Vogt, F. G., Kord, A. S. (2011). Development of quality-by-design analytical methods. Journal of Pharmaceutical Sciences, 100(3), 797-812. DOI: 10.1002/jps.22325.